GSK3B variations influence renoprotective responses to dapagliflozin in diabetic kidney disease

Jinfang Song, Yi Xu, Yongru Zhuang, Tingting Yang, Ya Chen, Changjiang Ying, Qian Lu, Tao Wang, Xiaoxing Yin · 2026

Read GSK3B variations influence renoprotective responses to dapagliflozin in diabetic kidney disease by Jinfang Song, Yi Xu, Yongru Zhuang, Tingting Yang, Ya Chen, Changjiang Ying, Qian Lu, Tao Wang, Xiaoxing Yin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427657.txt.

Description

Jinfang Song and co-authors investigate, in 2026, why a diabetes drug protects the kidneys well in some patients and weakly in others. Dapagliflozin lowers blood sugar and shields kidneys, yet its effect on urine protein varies widely between people. Working backward from clinic records, the team used a stability test plus protein profiling to hunt for the drug's direct partners. A protein called GSK3β emerged as one such partner.

Lab and animal checks showed the drug binds GSK3β and partly dials down its activity, which helped protect the kidney's filter cells. In a forward-looking patient group, one common variant in the GSK3B gene tracked with larger drops in urine protein on treatment. Testing that variant might one day help doctors predict who gains most renal benefit.

Catalog record

CREATORJinfang Song, Yi Xu, Yongru Zhuang, Tingting Yang, Ya Chen, Changjiang Ying, Qian Lu, Tao Wang, Xiaoxing Yin
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE104077
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13427657

Browse the full library · About the Tower of Babel